Drug Type Small molecule drug |
Synonyms SE-015, VE-015, VEL-015 |
Target |
Action inhibitors, stimulants |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT1 inhibitors), PP2A stimulants(Protein phosphatase 2A stimulants), PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaH2NaO4Se |
InChIKeyPRKRTJSKTGAVMH-UHFFFAOYSA-N |
CAS Registry13410-01-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Graves Ophthalmopathy | Phase 3 | - | 01 Oct 2015 | |
| Alzheimer Disease | Phase 2 | Australia | - | |
| Frontotemporal Dementia | Preclinical | Australia | 11 Oct 2024 | |
| Supranuclear Palsy, Progressive | Preclinical | Australia | 13 Oct 2023 | |
| Epilepsy | Preclinical | Australia | - |
Not Applicable | Dementia hyperphosphorylated tau | 12 | ajnjtcksqe(lqifzauuoi) = n=3 wzaygsiykb (olctddtogf ) View more | - | 31 Dec 2021 | ||
Not Applicable | Frontotemporal Dementia hyperphosphorylated tau | 15 | hyobrkmeki(xigjbylkaz) = n=4 jhyltfzyvd (cbhdwqfksr ) View more | - | 07 Dec 2020 |





